Immuno-oncology company Agenus Inc (NASDAQ: AGEN) reported on Tuesday the receipt of the US FDA clearance for the IND application for an allogeneic iNKT therapy as the potential therapy for patients in moderate to severe respiratory distress from COVID-19.
The company stated that AgenT-797 was submitted by its subsidiary, AgenTus Therapeutics.
Following the FDA clearance, the clinical trial of the allogeneic iNKT therapy for the treatment of patients with COVID-19 is expected to commence shortly. the company previously reported the FDA clearance of the IND for the use of allogeneic iNKTs for patients with cancer.
In conjunction, Dr Koen van Besien at Weill Cornell/New York Presbyterian Hospital will lead the COVID-19 trials.
By the end of this year, the company is contemplating of spinning out of AgenTus as well as issuing a portion of its holdings in AgenTus to Agenus shareholders in the form of a stock dividend.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government